Mucosal adjuvants
By using TGDK as a mucosal adjuvant to bind to vaccine antigens, the problem of insufficient immunity in mucosal vaccines was solved, achieving efficient and safe mucosal immune induction, especially a significant increase in IgG2a antibodies.
Patent Information
- Application Number
- CN201980063937.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-26
- Filing Date
- 2019-09-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In existing mucosal vaccines, inactivated antigens are difficult to induce a sufficient immune response when administered via mucosa, and traditional adjuvants such as LT and double-stranded RNA have safety issues, leading to side effects and insufficient immunity.
Tetragaloyl-D-lysine dendritic macromolecules (TGDK) are used as mucosal adjuvants, which are chemically bonded to vaccine antigens and enhance mucosal immune induction through M cell-specific binding.
TGDK significantly enhances mucosal immune responses, especially the production of IgG2a antibodies, providing the same immune induction effect as inactivated intact particle antigens, with high safety and avoiding the side effects of traditional adjuvants.
Smart Images

Figure CN112789056B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to mucosal adjuvants that enhance the induction of mucosal immunity to antigens. Background Art
[0002] Mucosal vaccines induce local immunity in the mucosa and systemic immune response by administering antigens through the mucosa, such as through the nose, thereby building a double line of defense against pathogens. On the other hand, vaccines that are used as mucosal vaccines are live vaccines with infectious properties or vaccines with special toxins with mucosal affinity as antigens. Other inactivated antigens alone cannot induce sufficient immunity and require a combination of adjuvants, etc.
[0003] As a method for inducing sufficient immunity with mucosal vaccines, infectious attenuated pathogens have been used in the past. However, attenuated live vaccines have strong side effects due to their infectiousness. For example, polio vaccine-related paralysis of oral live polio vaccines is a rare but unavoidable side effect, which is said to be caused by the neurotoxic recovery of the vaccine strain. Therefore, highly safe inactivated antigens should also be used in mucosal vaccines, but except for antigens such as special toxins, it is difficult to provide sufficient immunity through transmucosal administration. In order to improve this situation, the addition of mucosal adjuvants is considered, and cholera toxin and heat-labile toxin (LT) of toxigenic Escherichia coli are well known as representative mucosal adjuvants (Non-patent Documents 1-2).
[0004] However, in past clinical trials, nasal administration of LT caused facial nerve paralysis (Bell's palsy), and it was recognized that the use of toxin itself as an adjuvant has safety issues. In addition, other double-stranded RNA (polyI:C) (Patent Document 1) also has mucosal adjuvant activity, but it has not been put into practical use because it induces inflammation and cytokineemia.
[0005] In the recent development of nasal influenza vaccines in Japan, instead of the antigen of the commercially available influenza HA vaccine, i.e., split antigens, clinical trials were conducted using inactivated whole particles with higher immunogenicity as antigens (non-patent literature 3). This is because split antigens cannot induce sufficient immune responses by transmucosal administration, but inactivated whole particle antigens have side effects (local reactions and fever at the administration site) in subcutaneous administration, especially in young children, and are not currently circulated in the market. Therefore, it is expected that the split antigens with high safety can achieve the same degree of immune induction as inactivated whole particle antigens.
[0006] Tetragalloyl-D-lysine dendrimer (TGDK) is a molecule that specifically binds to antigen uptake cells present in the mucosa, namely Microfold cells (M cells) (Non-patent document 4). Therefore, by chemically bonding TGDK to antigens, etc., vaccine antigens can be effectively delivered to M cells, which can improve immune response. For example, Patent Document 2 discloses that TGDK-CH2-CH2-NH2 can be used as an intestinal immune activator by binding to peptides, proteins, lipids, polyethylene glycols or sugars via peptide bonds or Schiff bases. In addition, Patent Document 3 discloses that the covalent bond of Hub antigen, TGDK and fetuin can become a molecular mimic mucosal vaccine for HIV / AIDS.
[0007] However, the TGDK molecule itself is not known to have mucosal adjuvant activity at all.
[0008] Prior art literature
[0009] Patent Literature
[0010] Patent Document 1: Japanese Patent Application Laid-Open No. 2005-97267
[0011] Patent Document 2: International Publication No. 2007 / 052641
[0012] Patent Document 3: International Publication No. 2013 / 024859
[0013] Non-patent literature
[0014] Non-patent literature 1: Xu-Amano, J., H. Kiyono, RJ Jackson, HFStaats, K. Fujihashi, PD Burrows, CO Elson, S. Pillai, JRMc Ghee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and choleratoxin as adjuvant selectively induces Th2 cells in mucosa associatedtissues.J.Exp.Med.1993;178(4):1309-20
[0015] Non-patent document 2: Takahashi, I., M. Marinaro, H. Kiyono, RJ Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, JDClements, KLBost, JRMcGhee. 1996. Mechanisms formucosal immunogenicity and adjuvancy of Escherichia coli labileenterotoxin.J.Infect.Dis.1996;173(3):627-35
[0016] Non-patent document 3: Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Human vaccines&immunotherapeutics. 2013; 9(9): 1962-70.
[0017] Non-patent document 4: Misumi S, Masuyama M, Takamune N, et al. Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer Journal of Immunology, 2009; 182(10): 6061-6070 Summary of the invention
[0018] The present invention relates to providing a mucosal adjuvant useful for the preparation of a mucosal vaccine having high mucosal immunogenicity and high safety, and a mucosal vaccine composition containing the same.
[0019] The present inventors conducted studies in view of the above problems and unexpectedly found that TGDK, which has been chemically bonded to vaccine antigens and used to deliver the antigens to M cells, has adjuvant activity itself and can enhance the mucosal immunity-inducing ability of the antigens.
[0020] That is, the present invention relates to the following 1) to 10).
[0021] 1) A mucosal adjuvant consisting of TGDK.
[0022] 2) A mucosal adjuvant composition comprising TGDK and a pharmaceutically acceptable carrier.
[0023] 3) A mucosal vaccine composition comprising the mucosal adjuvant of 1) and an immunogen.
[0024] 4) The mucosal vaccine composition according to 3), wherein the immunogen is a whole particle or split antigen of influenza virus.
[0025] 5) A method for preparing the mucosal vaccine composition of 3) or 4), characterized by mixing TGDK and an immunogen.
[0026] 6) A TGDK for use as a mucosal adjuvant.
[0027] 7) A composition comprising TGDK and an immunogen for use in mucosal vaccine therapy.
[0028] 8) A use of TGDK for preparing a mucosal adjuvant.
[0029] 9) Use of a composition containing TGDK and an immunogen for preparing a mucosal vaccine.
[0030] 10) A mucosal vaccine therapy comprising administering a composition comprising TGDK and an immunogen to a subject in need thereof.
[0031] The mucosal adjuvant of the present invention can prepare a mucosal vaccine using a safe inactivated antigen. For example, a mucosal vaccine using a safer split antigen, such as the currently circulated influenza HA vaccine, can be provided, which can make a great contribution to the pharmaceutical industry as a preventive drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is the A / California / 07 / 2009 strain-specific IgG antibody titer in the split antigen administration group.
[0033] Figure 2 It is the B / Texas / 2 / 2013 strain-specific IgG antibody titer in the split antigen administration group.
[0034] Figure 3 It is the IgG antibody titer specific to the A / California / 07 / 2009 strain in the group administered with inactivated whole particle antigen.
[0035] Figure 4 It is the B / Texas / 2 / 2013 strain-specific IgG antibody titer in the group administered with inactivated whole particle antigen.
[0036] Figure 5 It is the geometric mean of the B / Texas / 2 / 2013 strain-specific IgG1 and IgG2a antibody titers in each group.
[0037] Figure 6 It is the IgG antibody titer specific for the A / California / 07 / 2009 strain.
[0038] Figure 7 It is the IgG antibody titer specific for the B / Texas / 2 / 2013 strain. DETAILED DESCRIPTION
[0039] In the present invention, "TGDK" is an abbreviation of tetragalloyl-D-lysine dendrimer, which refers to N2, N6-bis[N2, N6-bis(3, 4, 5-trihydroxybenzoyl)-lysyl]-N-(2-aminoethyl)-lysinamide. TGDK is well known as a target molecule for antigen uptake cells present in mucosa, namely M cells.
[0040] TGDK can be produced, for example, by using gallic acid and D-lysine and using a tetragalloyl-D-trilysyldiethylamine solid phase method (see Non-Patent Document 4 above).
[0041] As shown in the examples described below, relative to the group without the addition of TGDK, the titer of IgG that specifically binds to the antigen induced when the vaccine composition prepared by mixing influenza vaccine strains (split antigen / inactivated whole particle antigen) and TGDK is administered to mice by mucosal administration is significantly improved. In addition, when TGDK is added to the split antigen for immune induction, the IgG titer of the same degree as that when only the inactivated whole particle antigen is used to induce immunity is obtained. Moreover, if the geometric mean antibody titer (GMT) of IgG1 and IgG2a is looked at, the IgG2a with excellent infection defense ability against influenza virus rises significantly.
[0042] That is, when an immunogen (antigen) is administered mucosally, TGDK has a mucosal adjuvant activity that improves antibody induction ability, and therefore, TGDK becomes a mucosal adjuvant, and a composition containing TGDK and a pharmaceutically acceptable carrier can become a mucosal adjuvant composition. In addition, TGDK can be used to manufacture a mucosal adjuvant or a mucosal adjuvant composition.
[0043] In the present invention, the "mucosal adjuvant" refers to a substance that increases the immune response to an immunogen when the immunogen is administered mucosally.
[0044] Here, "mucosal administration" refers to the administration method via the mucosa, and "mucosa" refers to the inner wall of the middle cavity organs, especially the digestive organs, respiratory organs, urogenital organs, eyes, etc. of vertebrates that are open to the outside. Therefore, as such mucosal administration, for example, nasal administration (nasal administration), oral administration, vaginal administration, upper respiratory tract administration, alveolar administration, eye drop administration, etc. can be cited, but it is not limited to these.
[0045] The mucosal adjuvant or mucosal adjuvant composition of the present invention can be combined with an immunogen and administered mucosally. The administration may be simultaneous with, before, or after the administration of the immunogen.
[0046] The dosage of the mucosal adjuvant or mucosal adjuvant composition of the present invention can be appropriately determined depending on the administration target, administration method, administration form, and type of antigenic substance.
[0047] The mucosal adjuvant of the present invention can be combined with an immunogen to prepare a mucosal vaccine composition. The mucosal vaccine composition of the present invention can be prepared by mixing an immunogen and TGDK, and a pharmaceutically acceptable carrier can be further appropriately added to prepare an appropriate preparation. In the mucosal vaccine composition of the present invention, TGDK is not in a state of chemical bonding with the immunogen or other components, but exists in a free molecular state.
[0048] As "immunogens" (antigens), mucosal pathogens (such as viruses or pathogenic bacteria, etc.) or natural products refined from the pathogens, or proteins, peptides, polysaccharides artificially produced by methods such as genetic recombination, specifically complete virus particles, i.e., virions, incomplete virus particles, virion-constituting particles, viral non-structural proteins, proteins or glycoproteins from pathogens, infection defense antigens, neutralization reaction epitopes, etc., including substances with infectious ability and substances that lose the ability to infect (inactivated antigens). As inactivated antigens, for example, antigens inactivated by physical (such as X-ray irradiation, heat, ultrasound), chemical (formalin, mercury, alcohol, chlorine) and other operations can be cited, but are not limited to this. From the perspective of safety, the immunogen from the mucosal pathogen is preferably an inactivated antigen from the above-mentioned virus or pathogen.
[0049] As the virus, for example, varicella virus, measles virus, mumps virus, polio virus, rotavirus, influenza virus, adenovirus, herpes virus, severe acute respiratory syndrome (SARS) virus, human immunodeficiency virus (HIV), human papillomavirus, rubella virus, etc. can be mentioned, preferably influenza virus or human immunodeficiency virus, more preferably influenza virus. Influenza virus can use whole particle virus, but in the present invention, the split antigen obtained by lysing the virus particles and removing the lipid in the cytoplasmic sheath can be used.
[0050] Examples of the pathogenic bacteria include Bordetella pertussis, meningococci, influenza b b bacteria, pneumococci, tuberculosis bacilli, Vibrio cholerae, and Corynebacterium diphtheriae.
[0051] Examples of the dosage form of the mucosal vaccine composition include liquid preparations, suspension preparations, and powder preparations.
[0052] Examples of liquid preparations include those dissolved in purified water, buffer solution, etc. Examples of suspension preparations include those suspended in purified water, buffer solution, etc. together with methylcellulose, hydroxymethylcellulose, polyvinylpyrrolidone, gelatin, casein, etc. Examples of powder preparations include those fully mixed with methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, etc.
[0053] To these preparations, commonly used absorption enhancers, surfactants, preservatives, stabilizers, anti-humidifying agents, moisturizing agents, solubilizing agents and the like may be added as necessary.
[0054] In addition, the mucosal vaccine composition of the present invention may contain an adjuvant other than TGDK as long as the immunogenicity and safety of the vaccine are not impaired.
[0055] The amount of the immunogen contained in the mucosal vaccine composition of the present invention is not particularly limited as long as it is an amount sufficient to produce antigen-specific IgG, and can also be appropriately set by considering the ratio with the TGDK used in combination. For example, when a split antigen of influenza virus is used as an antigen, it is sufficient to contain it within the range of 1 to 60 μg HA (HA conversion) for a single administration, and more preferably 9 to 15 μg HA (HA conversion). The above concentration is a value obtained by measuring the concentration of HA protein using a test method specified by WHO and national standards such as a monovariate radial immunodiffusion test method and a HA content method.
[0056] The content of TGDK in the mucosal vaccine composition can be appropriately adjusted in consideration of the antibody titer, but may be contained within the range of, for example, 0.03 to 30 μg per single administration, more preferably 0.03 to 0.3 μg.
[0057] The administration route of the vaccine composition of the present invention is not particularly limited, and may be oral administration or parenteral administration (eg, nasal administration, eye drop administration), for example, administration by dripping, spraying or applying into the nasal cavity or oral cavity.
[0058] The adjuvant composition or vaccine composition of the present invention can be administered to humans and mammals other than humans, preferably humans. Mammals other than humans include, for example, mice, rats, hamsters, guinea pigs, rabbits, pigs, cows, goats, horses, sheep, dogs, cats, monkeys, gorillas, chimpanzees, etc.
[0059] Example
[0060] Hereinafter, the present invention will be described in more detail by way of Examples, but the present invention is not limited to these Examples.
[0061] Example 1
[0062] (1) The stock solutions of influenza HA vaccine "Seiken" A / H1N1 subtype (A / California / 07 / 2009 strain) and B / Yamagata system (B / Texas / 2 / 2013 strain) were used as split antigens, and the split antigens were mixed so that the hemagglutinin of each strain was 1 μg per 10 μL, and TGDK was added so that the final concentration was 0.03 to 30 μg / 10 μL. In addition, as controls, a dosing solution without adjuvant addition and a dosing solution in which gallic acid was added as a TGDK control to a concentration of 30 μg / 10 μL were prepared (Table 1). Gallic acid was used as a TGDK control because TGDK is obtained by binding 4 molecules of gallic acid to the primary amine of a skeleton formed by 3 molecules of lysine. In addition, inactivated whole particle antigens of the A / H1N1 subtype (A / California / 07 / 2009 strain) and the B / Yamagata system (B / Texas / 2 / 2013 strain) were mixed in the same manner as the split antigens so that the hemagglutinin of each strain became 1 μg per 10 μL, and the administration solution of each inactivated whole particle antigen was prepared so that TGDK became 0.03 or 0.3 μg and gallic acid became 30 μg (Table 1).
[0063] The preparation of the inactivated whole particle antigen used in this example is as follows. It was inoculated into the chorioallantoic cavity of 12-day-old developing eggs, and the chorioallantoic fluid was collected after culturing for 2 days. The collected chorioallantoic fluid was filtered and clarified with a filter, then adsorbed on barium sulfate, and the influenza virus was eluted with a 12% sodium citrate solution to recover the influenza virus. The recovered virus was further replaced with 6.7mM phosphate buffered saline (pH7.2) by ultrafiltration, and after the buffer replacement, the fraction containing the influenza virus was recovered by sucrose density gradient centrifugation for purification. β-propiolactone was added as an inactivator to the purified influenza virus in a final concentration of 0.05%, and the infectivity of the influenza virus was inactivated by a reaction at 4°C for 24 hours. After the inactivation reaction, the buffer was replaced with 6.7mM phosphate buffered saline (pH7.2) containing 1w / w% sucrose by ultrafiltration (MWCO: 100000), and it was made into an inactivated whole particle vaccine.
[0064] (2) The dosing solution prepared as described above (Table 1) was administered to BALB / c mice (female, 5 weeks old) twice at an interval of 3 weeks (a total of 10 μL) per nostril (8 mice per group), and whole blood was collected 2 weeks after the second administration. Serum was prepared by centrifugation, and the IgG (Total IgG) titer that specifically binds to the A / California / 07 / 2009 strain and the B / Texas / 2 / 2013 strain was measured. In addition, the titers of IgG1 and IgG2a, which are IgG subclasses, were measured for the serum of the group without adjuvant addition and the group with TGDK0.3 μg added for split antigen and inactivated whole particle antigen, and the antibody titer specific to the B / Texas / 2 / 2013 strain was measured.
[0065]
[0066] (3) The IgG titers of the split antigen administration groups (A to F) and the inactivated whole particle antigen administration group without adjuvant (G) were as follows: Figure 1 and 2 As shown. By adding 0.03 to 30 μg of TGDK to the split antigen for each administration, the antigen-specific IgG titer in the blood was higher than that without the addition of adjuvant in all strains, and was at the same level as that of the inactivated whole particle antigen. In particular, for the IgG titer of the A / California / 07 / 2009 strain, the group with the addition of 0.03 to 0.3 μg of TGDK, and for the IgG titer of the B / Texas / 2 / 2013 strain, the group with the addition of 0.03 to 3 μg of TGDK showed significantly higher IgG titers than those without the addition of adjuvant (Mann-Whitney U test, p < 0.05). In addition, when gallic acid was added to the split antigen, the IgG titer for the A / California / 07 / 2009 strain was at the same level as that without the addition of adjuvant, and the IgG titer for the B / Texas / 2 / 2013 strain was significantly reduced compared to the absence of adjuvant. Although polyphenols have antioxidant and immune-activating effects, in this example, it is believed that a single molecule of gallic acid does not enhance the antibody-induced adjuvant activity, and the structure of TGDK, in which four molecules of gallic acid are bound to the primary amine of a skeleton formed by three molecules of lysine, is important for exerting adjuvant activity.
[0067] Next, the results of the groups (H to J) administered with inactivated whole particle antigen are shown in Figure 3 and 4, it can be seen that, similar to the split antigen, by administering 0.03 or 0.3 μg of TGDK to the inactivated whole particle antigen, the IgG titer for each strain was increased. By adding gallic acid, the IgG titer for the A / California / 07 / 2009 strain was the same as that of the group without adjuvant addition, and the IgG titer for the B / Texas / 2 / 2013 strain was reduced. Therefore, even in the inactivated whole particle antigen, the same results as the split antigen can be obtained, but the effect of increasing the IgG titer caused by the addition of TGDK in the inactivated whole particle antigen is smaller than that in the split antigen. This is because the inactivated whole particle antigen itself has high immunogenicity, but it can be confirmed that TGDK exerts adjuvant activity for nasal administration in both antigens (split antigen and inactivated whole particle antigen) with different immunogenicity.
[0068] in addition, Figure 5 The geometric mean antibody titer (GMT) of IgG1 and IgG2a in each group is shown, and it can be seen that IgG2a significantly increased due to the addition of TGDK in both split antigens and inactivated whole particle antigens. Compared with IgG1 induced by Th2 type response, IgG2a induced by Th1 type response has excellent protection against influenza virus infection, so it is expected that the effectiveness will be further improved by adding TGDK.
[0069] Reference Example 1
[0070] (1) The adjuvant activity of TGDK administered subcutaneously in the test groups shown in Table 2 was evaluated using the same antigen as in Example 1. In this evaluation, Alm (Imject Alum, manufactured by Thermo Fisher Scientific) which has been used as an adjuvant for subcutaneous administration was added as a control.
[0071]
[0072] (2) The IgG titer against the A / California / 07 / 2009 strain is shown in Figure 6 , the IgG titer for B / Texas / 2 / 2013 strain is shown in Figure 7 For each strain, the IgG titer of the group with TGDK added was the same as that of the group with split antigen alone, and no adjuvant activity was confirmed. On the other hand, in the Alm and inactivated whole particle administration groups (WV), higher IgG titers were shown than those of the group with split antigen alone. It should be noted that in subcutaneous administration, the IgG titer of the group with gallic acid addition was the same as that of the group with split antigen alone in each strain, and TGDK and gallic acid, which are gallic acid derivatives, did not have adjuvant activity in subcutaneous administration.
Claims
1. A mucosal vaccine composition comprising a mucosal adjuvant and an immunogen, wherein the mucosal adjuvant is composed of tetragalloyl-D-lysine dendrimer (TGDK), In the mucosal vaccine composition, TGDK is not in a state of chemical bonding with the immunogen, but exists in a free molecular state; The content of TGDK in the mucosal vaccine composition is 0.03 to 0.3 μg.
2. The mucosal vaccine composition according to claim 1, wherein The immunogens are whole particles or split antigens of influenza virus.
3. A method for preparing the mucosal vaccine composition according to claim 1 or 2, characterized in that: Tetragalloyl-D-lysine dendrimer, TGDK, and the immunogen were mixed.
4. A composition comprising a tetragalloyl-D-lysine dendrimer, TGDK, and an immunogen for use in mucosal vaccine therapy, In the composition, TGDK is used as a mucosal adjuvant, and TGDK is not in a state of chemical bonding with the immunogen, but exists in a free molecular state; The content of TGDK in the composition is 0.03-0.3 μg.
5. Use of a composition comprising tetragalloyl-D-lysine dendrimer, TGDK, and an immunogen for the manufacture of a mucosal vaccine, In the manufactured mucosal vaccine, TGDK is used as a mucosal adjuvant, and TGDK is not in a state of chemical bonding with the immunogen, but exists in a free molecular state; The content of TGDK in the composition is 0.03-0.3 μg.
